disposed in the lumen capable of absorbing intraocular fluid via a passive filling action into the sample chamber.

Potential Commercial Applications:

- Ocular therapeutics
- Macular degeneration
- Diabetic retinopathy
- Retinal vein occlusion Competitive Advantages:
- Small sample volumes
- Disposable
- Personalized medicine Development Stage:
- Prototype
- Early-stage

Inventors: Henry E. Wiley (NEI), Terrence M. Philips (NIBIB), Fredrick L. Ferris (NEI), Heather Kalish (NIBIB).

Intellectual Property: HHS Reference No. E–233–2010/0—U.S. Provisional Patent Application No. 61/533,908 filed September 13, 2011.

*Licensing Contact:* Michael Shmilovich, Esq.; (301) 435–5019; *mish@codon.nih.gov.* 

Collaborative Research Opportunity: The National Eye Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize intraocular therapeutic delivery. For collaboration opportunities, please contact Alan E. Hubbs, Ph.D. at (301) 594–4263 or hubbsa@mail.nih.gov.

### Bacteria/Biofilm Resistant Implantable Medical Device

Description of Technology: Available for licensing and commercial development is a medical device resistant to a biological barrier such as a bacterial biofilm, fibrin sheath, and/or clot formation. An electric current is introduced through an electrically conductive surface of the device (e.g., a catheter) on which a biofilm, fibrin sheath, or clot may form to inhibit formation. The electrically conductive surface can extend along an entire surface of the device (for example extending entirely from the proximal to distal end of a catheter), or a portion thereof such as at the tip.

Potential Commercial Applications:

- Biofilm resistant medical devices
- Antimicrobial methods
- Antimicrobial protection of implanted medical device
- Vascular access devices Competitive Advantages: Nondegradable antimicrobial methods. Development Stage:
  - Prototype
  - · Early-stage

Inventors: Bradford Wood and Ziv Neeman (NIHCC).

Intellectual Property: HHS Reference No. E–078–2005—U.S. Provisional Patent Application 61/501,065 filed June 24, 2011.

Licensing Contact: Michael Shmilovich, Esq.; (301) 435–5019; mish@codon.nih.gov.

Dated: November 16, 2011.

#### Richard U. Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2011–30109 Filed 11–21–11; 8:45 am]

BILLING CODE 4140-01-P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **National Institutes of Health**

# Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Program Project: Mitosis and Mejosis.

Date: December 13-14, 2011.

Time: 9 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

Contact Person: Elena Smirnova, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5187, MSC 7840, Bethesda, MD 20892, (301) 435– 1236, smirnove@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: November 15, 2011.

### Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011–30118 Filed 11–21–11; 8:45 am] BILLING CODE 4140–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **National Institutes of Health**

## Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Psychomotor Behavior After Chemotherapy.

Date: November 30, 2011. Time: 12:30 p.m. to 2 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Biao Tian, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3089B, MSC 7848, Bethesda, MD 20892, (301) 402–4411, tianbi@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Review of HIV/AIDS Clinical Studies and Epidemiology Grant Applications.

Date: December 9, 2011.

Time: 12 p.m. to 3 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

Contact Person: Mark P. Rubert, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5218, MSC 7852, Bethesda, MD 20892, (301) 435– 1775, rubertm@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Studies in Prevention and Health Disparites HIV/AIDS.

Date: December 14–15, 2011.

Time: 10 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

Contact Person: Robert Freund, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5216, MSC 7852, Bethesda, MD 20892, (301) 435– 1050, freundr@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Member Conflict: Dermatology.

Date: December 19, 2011. Time: 2 p.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Jean D. Sipe, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4106, MSC 7814, Bethesda, MD 20892, (301) 435– 1743, sipej@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: November 16, 2011.

#### Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011–30101 Filed 11–21–11; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **National Institutes of Health**

### National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel, Predoctoral Training in Cardiovascular Research.

Date: December 15, 2011.

Time: 1 p.m. to 2 p.m.

*Agenda:* To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Stephanie L Constant, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7189, Bethesda, MD 20892, (301) 443–8784, constantsl@nhlbi.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: November 16, 2011.

#### Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011–30099 Filed 11–21–11; 8:45 am]

BILLING CODE 4140-01-P

# DEPARTMENT OF HOMELAND SECURITY

## U.S. Citizenship and Immigration Services

Agency Information Collection Activities: Form N-300; Revision of an Existing Information Collection; Comment Request

**ACTION:** Notice.

The Department of Homeland Security, U.S. Citizenship and Immigration Services (USCIS) will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995. The information collection was previously published in the Federal Register on August 24, 2011 at 76 FR 52961, allowing for a 60-day public comment period. USCIS received two comments in connection with that notice, which informed the public that USCIS will be requesting revision of this information collection.

The purpose of this notice is to allow an additional 30 days for public comments. Comments are encouraged and will be accepted until December 22, 2011. This process is conducted in accordance with 5 CFR 1320.10.

Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the Department of Homeland Security (DHS), and to the Office of Management and Budget (OMB) USCIS Desk Officer. Comments may be submitted to: USCIS, Chief, Regulatory Products Division, Office of the Executive Secretariat, Clearance Office, 20 Massachusetts Avenue, Washington, DC 20529–2020. Comments may also be submitted to

DHS via facsimile to (202) 272–0997 or via email at *uscisfrcomment@dhs.gov*, and to the OMB USCIS Desk Officer via facsimile at (202) 395–5806 or via email at *oira\_submission@omb.eop.gov*. Please do not submit requests for individual case status inquiries to these addresses. If you are seeking information about the status of your individual case, please check "My Case Status" online at *https:* //egov.uscis.gov/cris/Dashboard, or call the USCIS National Customer Service Center at 1–800–375–5283 (TTY 1 (800) 767–1833).

When submitting comments by email please make sure to add OMB Control Number 1615–0078 in the subject box. Written comments and suggestions from the public and affected agencies should address one or more of the following four points:

(1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
(2) Evaluate the accuracy of the

(2) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(3) Enhance the quality, utility, and clarity of the information to be collected; and

(4) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

# Overview of This Information Collection

- (1) Type of Information Collection: Revision of an existing information collection.
- (2) *Title of the Form/Collection:* Application to File Declaration of Intention.
- (3) Agency form number, if any, and the applicable component of the Department of Homeland Security sponsoring the collection: Form N–300; U.S. Citizenship and Immigration Services (USCIS).
- (4) Affected public who will be asked or required to respond, as well as a brief abstract: Primary: Individuals or households. Form N–300 will be used by permanent residents to file a declaration of intention to become a citizen of the United States. This collection is also used to satisfy documentary requirements for those seeking to work in certain occupations